{
  "id": 10765652,
  "title": "GLP-1, ADHD medication costs leading surge in drug insurance claims: report",
  "url": "https://urgent.news/2026/09/29/glp-1-adhd-medication-costs-leading-surge-in-drug-insurance-claims",
  "topic": "world",
  "section": "World",
  "published": "2026-09-29T19:50:37.000Z",
  "source": {
    "name": "Global News",
    "slug": "global-news",
    "url": "https://globalnews.ca/news/12077482/glp1-adhd-medication-costs-surge-insurance-claims-report/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Drug insurance claims across Canada have seen a significant surge in 2025, with a 9.5% increase in costs according to a report by GreenShield insurance company. The rise is largely attributed to the growing demand for treatments related to diabetes, obesity, and other chronic conditions. GLP-1 medications, such as semaglutide, have seen a significant rise in costs, with a 47.7% increase compared to 2024. Semaglutide accounted for 6.6% of total drug insurance costs in Canada in 2025 and was the top product by total drug cost. The average claimant spent $2,489 on drugs like Ozempic, Rybelsus, and Wegovy for diabetes and weight management. The report also noted a significant rise in ADHD medication costs, particularly for methylphenidate and lisdexamfetamine, with a 23.1% increase in claims among people aged 35-44.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}